Bcl‐xL mediates increased production of humanized monoclonal antibodies in Chinese hamster ovary cells
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Enhanced product yields, reduction in throughput time, improved cost‐effectiveness and product quality are examples of benefits gained by delaying apoptotic cell death in bioreactors. To examine the effect on recombinant protein production, bcl‐x L was overexpressed in a CHO cell line secreting humanized monoclonal antibody directed against the α1β1 integrin. When cell lines overexpressing bcl‐x L were compared to the parent, cell viability was increased by 20% and titers by 80%. Total viable cell densities were similar and specific productivities were enhanced by almost two‐fold on scale‐up to bioreactors. Comparison in a chemically defined media demonstrated an even greater sustained viability in bcl‐x L expressing cells by 50% and up to 90% increase in titer with no impact on product quality. Caspase 3 activities were monitored as a marker for apoptotic cell death. In the presence of Bcl‐x L, caspase activities were reduced to background levels. The role of Bcl‐x L in protecting cells from premature death was further examined in studies performed in the presence of NaBu, at concentrations known to trigger cell death. Results demonstrated that cells expressing bcl‐x L retained 88% cell viability with >2 fold increase in titer. Bcl‐x L was similarly overexpressed in a different CHO cell line producing a humanized mAb against the chemokine MCP1. Once again, production titer was increased by 80% and viability by 75%. Together the studies have shown that overexpression of bcl‐x L in production cell lines was able to significantly increase the titer by enhancing both the specific activity and total cell viability while maintaining product quality. © 2005 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reverse engineering of biological complexity
Csete, M. E., & Doyle, J. C. (2002) · Science · doi:10.1126/science.1069981 · Cited by 1,215
BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis
Danial, N. N., Gramm, C. F., Scorrano, L., Zhang, C.-Y., Krauss, S., Ranger, A. M., Robert Datta, S., Greenberg, M. E., Licklider, L. J., Lowell, B. B., et al. (2003) · Nature · doi:10.1038/nature01825 · Cited by 705
Heiden, M. G. V., Chandel, N. S., Schumacker, P. T., & Thompson, C. B. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80307-x · Cited by 505
Vander Heiden, M. G., Li, X. X., Gottleib, E., Hill, R. B., Thompson, C. B., & Colombini, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101590200 · Cited by 372
Cited by
Kim, J. Y., Kim, Y.-G., & Lee, G. M. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3758-5 · Cited by 801
Mammalian cell protein expression for biopharmaceutical production
Zhu, J. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.022 · Cited by 491
Huang, Y., Hu, W., Rustandi, E., Chang, K., Yusuf‐Makagiansar, H., & Ryll, T. (2010) · Biotechnology Progress · doi:10.1002/btpr.436 · Cited by 350
The art of CHO cell engineering: A comprehensive retrospect and future perspectives
Fischer, S., Handrick, R., & Otte, K. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.10.015 · Cited by 312
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
“As for anti-apoptosis engineering, genes of the Bcl-2 family (Bcl-2, Bcl-xL and Mcl-1) were overexpressed in a variety of CHO cell lines (Kim and Lee, 2000; Tey et al., 2000; Meents et al., 2002; Chiang and Sisk, 2005; Kim et al., 2009b; Majors et al., 2009).”
Background
Metadata
- Authors
- Chiang, G. G., & Sisk, W. P.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2005-06-28
- Volume
- 91
- Issue
- 7
- Pages
- 779-792
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W1977176918
- Cited by
- 92
- References
- 4
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.